NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.
Details of the agreement were not disclosed.
Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.
Lexicon also sells subscriptions to its LexVision database of mouse gene-knockout data, which includes physiological data such as measurements of whole blood-cell count, X-rays, MRI and CT scans, and certain neurological tests.
Last week, Lexicon announced that GlaxoSmithKline agreed to a multi-year, non-exclusive sublicense to Lexicon Genetics' gene targeting technologies. Under the terms of the agreement, GlaxoSmithKline will pay an undisclosed one-time fee.